Ticker brief · 2026-08-16
HIMS HIMS & HERS HEALTH INC
Growth reaccelerates, but margins and crowded optimism cap conviction
Communications · Internet
Lean: mixedlast close
$28.84
1 day
-8.9%
14 days
+2.5%
mkt cap
$8.5B
signals 14d
538
authors 14d
140
crowd 14d
-0.0σfade
HIMS delivered genuine revenue, subscriber and international acceleration, but high-credibility bears correctly emphasize deteriorating margins and profitability. The key late-week shift was Oscar confirming partnership talks, potentially opening employer-funded distribution, while the Hers UK launch added tangible international execution. Options priced a 14.5% earnings move, yet muted realized volatility and clustered buy plans near $25-$28 imply a range trade rather than clean momentum.
BULL CAMP
Bulls argue raised guidance, record subscriber additions, higher ARPU and international expansion validate a reaccelerating platform. AI efficiencies, peptides and new distribution could expand both addressable market and lifetime value.
Key voices@MisterInversorMEDIUMC+0.71@TheLongInvestMEDIUM-HIGHC-1.78@AlphaSenseIncMEDIUM-HIGHB+1.04@BastianelliLoreMEDIUMA+1.47
“Non-US revenue grew 1,641%, supporting the case that acquired international operations can become a meaningful second growth engine.”— @TheLongInvest · tweet ↗
BEAR / SKEPTIC
Bears argue growth is being purchased through lower-margin weight-loss products, acquisitions and escalating investment, while organic US momentum remains insufficiently disclosed. The EPS miss, EBITDA reduction and regulatory exposure challenge financial quality.
Key voices“Subscriber growth was offset by margin compression, higher expenses and a sizable EPS miss.”— @schaeffers · tweet ↗
Hypotheses15direction · basis · magnitude · supporters — NEW = first seen this week
▲Revenue reacceleration and raised 2026 guidance confirm that HIMS has resumed durable top-line growth despite the mixed earnings reaction.
@himshouseLOW-MEDIUMC+1.004s@TheStockerManMEDIUMB-0.215s@MisterInversorMEDIUMC+0.713s@growthrapidlyMEDIUMC-1.634s@AlphaSenseIncMEDIUM-HIGHB+1.043s · insight@ManuInvestsMEDIUM-HIGHA+0.251s · insight+1 more
▲Record subscriber additions and rising ARPU demonstrate improving customer acquisition and monetization, supporting continued compounding of the core platform.
@himshouseLOW-MEDIUMC+1.002s@TheStockerManMEDIUMB-0.211s@DrTomsLensLOW-MEDIUMC-1.023s@StockSavvyShayHIGHB-2.151s · insight@cfaryanoconnellMEDIUMC-1.481s@fiscal_aiMEDIUM-HIGHB-0.371s · insight+1 more
▲Eucalyptus and rapid non-US growth are creating a scalable international revenue engine that can diversify HIMS beyond its domestic business.
@himshouseLOW-MEDIUMC+1.006s@TheLongInvestMEDIUM-HIGHC-1.781s@AlphaOwlTradingLOW-MEDIUMC-2.041s@LuxAlgoMEDIUMC+0.361s@TrendSpiderMEDIUM-HIGHC-1.011s
▲Project Galen and increased AI investment can improve personalization, engagement and labor efficiency, strengthening HIMS operating leverage over time.
@himshouseLOW-MEDIUMC+1.005s@TheStockerManMEDIUMB-0.213s@Investinc_IntelLOW-MEDIUMC+0.691s@MatiasManuel71LOW-MEDIUMB-0.123s@BastianelliLoreMEDIUMA+1.471s · insight
▲The up-to-$30M peptide technology-transfer agreement enables in-house API manufacturing and supports multiple commercially significant product launches before year-end.
@himshouseLOW-MEDIUMC+1.006s@Investinc_IntelLOW-MEDIUMC+0.692s@MatiasManuel71LOW-MEDIUMB-0.122s@EmmanuelInvestLOW-MEDIUMC-1.111s@IngJuanPa7LOW-MEDIUMB-1.611s · insight
▲A rumored FDA Category 1 change for two peptides before October ends could accelerate HIMS peptide launches and unlock substantial upside.
▲A potential Oscar marketplace partnership could add employer-funded distribution, reduce acquisition costs and broaden HIMS access to insured healthcare customers.
@himshouseLOW-MEDIUMC+1.001s@Investinc_IntelLOW-MEDIUMC+0.694s
▼Weight-loss products, international expansion and investment are compressing gross margins and reducing EBITDA, weakening the quality of reported growth.
@himshouseLOW-MEDIUMC+1.004s@schaeffersHIGHC+3.184s@wallstengineHIGHB-1.901s@1000xStocksMEDIUMC+1.092s@OpenOutcrierMEDIUM-HIGHC1s@AhmedShwwLOW-MEDIUMC+0.291s
▼The severe EPS miss and swing to substantial losses indicate weak financial quality despite management's stronger revenue outlook.
@schaeffersHIGHC+3.185s@Sam_BadawiMEDIUM-HIGHC-1.462s@scetraderMEDIUM-HIGHC+1.591s@optionscjpMEDIUMC-1.281s@Kev_Capital_TALOW-MEDIUMC+2.111s@ondrejsluneckoMEDIUMC+0.201s+1 more
▼Acquisition effects, subscriber-definition ambiguity and declining app rankings obscure organic US growth and may signal weakening customer momentum.
@himshouseLOW-MEDIUMC+1.004s@TheStockerManMEDIUMB-0.211s@InvestJourneyXLOW-MEDIUMC-0.381s@alexcapital01LOW-MEDIUMC-0.352s@wallstengineHIGHB-1.901s
◆HIMS remains a binary technical setup, with strength above $31 targeting $39 and rejection exposing $24-$28 support.
@Fibonacci_TAMEDIUMC-1.636s@Arturraposo1RLOW-MEDIUMB-0.662s@chad_venturesMEDIUMC-1.841s@JonEtradesLOW-MEDIUMC-1.831s
▲New institutional positions, reduced put exposure and reported re-accumulation indicate improving sponsorship after the earnings reset.
▼FTC allegations involving private health-data sharing with META and SNAP threaten legal costs, customer trust and HIMS valuation.
▲The official Hers app launch in the UK provides tangible evidence that HIMS can localize and extend its platform internationally.
@Investinc_IntelLOW-MEDIUMC+0.691s
◆Extreme $100, $1,000 and half-trillion-dollar projections reflect coordinated promotional enthusiasm unsupported by the quarter's profitability evidence.
@TheRealBirnbaumLOW-MEDIUMC-2.414s@MisterInversorMEDIUMC+0.715s@NighthawkTradezLOW-MEDIUMC-0.273s@alc2022MEDIUM-HIGHC-0.162s
Direct calls5authors taking explicit directional positions
@TheStockerManMEDIUMB-0.21
HIMS will reach $150 by 2030.
@TheProfInvestorMEDIUM-HIGHC+0.14
Stay long while $25 holds, targeting $43.
@optionscjpMEDIUMC-1.28
Buy 10,000 shares near $25 and sell puts on red days.
@aboutheoptionsMEDIUMC
The August 21 $28 put remains actionable.
@JavierSanzLOW-MEDIUMC-1.35
Short HIMS.
Sellside activity12
Truist reiterate PT 27Reiterated Hold while discussing July trends and expected guidance.
Truist target PT 23Hold rating accompanied by card data indicating moderating GLP-1 activity.
Morgan Stanley pt_raise PT 28 (from 21)Raised target while retaining Equalweight.
Citi pt_cut PT 33 (from 35)Retained Neutral and cited execution risk.
BofA pt_raise PT 32 (from 30)Retained Neutral following mixed guidance.
Needham pt_raise PT 42 (from 35)Reiterated Buy based on durable growth.
Needham pt_raise PT 45 (from 35)A separate relay reported a $45 target, conflicting with multiple $42 reports.
Canaccord reiterate PT 40Reiterated Buy on accelerating growth and new-market momentum.
Deutsche Bank pt_raise PT 26 (from 25)Maintained Hold.
TD Cowen pt_raise PT 30 (from 25)Maintained Hold.
Leerink pt_raise PT 30 (from 25)Raised its post-earnings price target.
Evercore noteAcknowledged improving growth but remained concerned about declining profitability and another guide cut.
News / data points5discrete events + data quoted by authors
@himshouseLOW-MEDIUMC+1.00
Revenue guidance increased from $2.8B to $3.2B while adjusted EBITDA guidance declined from $337.5M to $300M.
@himshouseLOW-MEDIUMC+1.00
Quarterly subscriber additions reached a record 307K, 70% above the previous high.
@StockSavvyShayHIGHB-2.15
ARPU reached a record $92, nearly 60% higher over two years.
@TheLongInvestMEDIUM-HIGHC-1.78
Non-US segment revenue increased 1,641%, demonstrating rapid international scaling.
@himshouseLOW-MEDIUMC+1.00
Oscar confirmed talks with Hims regarding a potential healthcare-marketplace partnership.
Position disclosures3skin in the game
@TheStockerManMEDIUMB-0.21
HIMS represented about 25% of the long-term portfolio, with no further addition planned immediately.
@Arturraposo1RLOW-MEDIUMB-0.66
HIMS represented 30% of a portfolio with 50% healthcare exposure.
@tastyliveshowHIGHB+0.08
Relayed an existing HIMS short position with stops already placed.
Desk readconvergence assessment
There is strong convergence on revenue acceleration but little agreement on its quality: bulls emphasize 307K net additions, $92 ARPU and international growth, while bears focus on margin compression, the EBITDA reduction and opaque organic growth. Bullish volume is amplified by lower-credibility or cold-hand accounts such as Investinc_Intel at -3.01 and TheStockerMan at -0.70, whereas several high-credibility bear reporters independently emphasized profitability, although some also have negative recent scores. The prior book long lost 3.15% and HIMS is no longer held; a durable margin stabilization with clean organic US disclosure would improve the view, while another profitability cut or failed Oscar and FDA catalysts would make the bear case dominant.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 99% mid · 64 pctile own 1y | IV/HV 1.13× (as of 2026-08-06) |
| Skew — 25Δ RR 30d | +0.112 93 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +13.89 elevated | 5-session Δ +2.49 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2026-05-12 (z=2.4) |
| Crowd state | victory-lap fade active | flagged 2026-07-06 (MC3f / MC3L exhaustion) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-14 → 2026-08-28 · now +0.27 (−1 bearish … +1 bullish)
Who spoke140
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Investinc_Intel | C | +0.69 | 58 | +0.48 |
| @himshouse | C | +1.00 | 56 | +0.14 |
| @TheStockerMan | B | -0.21 | 32 | +0.53 |
| @Arturraposo1R | B | -0.66 | 20 | +0.39 |
| @MisterInversor | C | +0.71 | 19 | +0.62 |
| @TheLongInvest | C | -1.78 | 19 | +0.47 |
| @Fibonacci_TA | C | -1.63 | 12 | -0.01 |
| @StockTrader_Max | C | -2.05 | 12 | +0.64 |
| @DrTomsLens | C | -1.02 | 11 | +0.63 |
| @optionscjp | C | -1.28 | 11 | +0.23 |
| @YodaStockInvest | C | -3.66 | 11 | +0.60 |
| @alc2022 | C | -0.16 | 11 | +0.66 |
| @harry03994688 | A | -0.79 | 9 | +0.59 |
| @StockChaser_ | C | -2.36 | 9 | +0.52 |
| @growthrapidly | C | -1.63 | 8 | +0.52 |
| @BastianelliLore | A | +1.47 | 8 | +0.58 |
| @TheRealBirnbaum | C | -2.41 | 7 | +0.51 |
| @itsCblast | C | -0.15 | 7 | +0.67 |
| @AlphaOwlTrading | C | -2.04 | 6 | +0.73 |
| @PeloSwing | C | -0.75 | 6 | +0.28 |
| @Chill_Investing | C | -1.24 | 6 | +0.13 |
| @johnscharts | C | -2.20 | 6 | +0.66 |
| @PrimeTrading_ | C | -4.67 | 6 | +0.19 |
| @duketoyo123 | C | -0.36 | 5 | +0.30 |
| @MitchMartan98 | C | -0.69 | 5 | +0.58 |
Recent signals30of 538 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @Chill_Investing | +0.20 | Recaps nine winning closed trades and $11,142 realized gains; tickers capped at six. | — | tweet ↗ |
| 2026-08-28 | @himshouse | +0.20 | Unverified rumor says a large 503B pharmacy restarted GLP-1 production | — | tweet ↗ |
| 2026-08-28 | @BTDenominator | -0.50 | Hawkish rate outlook is framed as damaging growth, risk assets and AI stocks. | — | tweet ↗ |
| 2026-08-28 | @DeNebulord | -0.30 | Warns that HIMS has substantial legal and regulatory exposure capable of causing violent moves. | — | tweet ↗ |
| 2026-08-28 | @himshouse | -0.10 | Reports 222,000 units of unapproved retatrutide in a U.S.-bound shipment | — | tweet ↗ |
| 2026-08-28 | @TheRealBirnbaum | +0.60 | Expresses confidence in HIMS management and views IREN as quantitatively cheap. | — | tweet ↗ |
| 2026-08-28 | @InvestVerified | -0.65 | HIMS broke an uptrend and could fall toward support near $27.50. | — | tweet ↗ |
| 2026-08-28 | @Arturraposo1R | +0.10 | Reports a 9% decline while framing it as a test of patient investors. | — | tweet ↗ |
| 2026-08-28 | @invertiramateur | +0.85 | Bought 3 HIMS shares at $29 and expects $41 soon; may sell MNDY to add favored names. — Reports a new HIMS purchase, bullish target and thesis, while considering selling MNDY. | — | tweet ↗ |
| 2026-08-28 | @TheStockerMan | +0.70 | Builds a long-term bullish framework for HIMS and DUOL despite near-term margin and bookings concerns. | — | tweet ↗ |
| 2026-08-28 | @TheStockerMan | +0.75 | Argues HIMS's margin sacrifice funds customer growth, international expansion, and a broader health platform. | — | tweet ↗ |
| 2026-08-28 | @TheStockerMan | +0.70 | Expects short-term volatility but says the long-term HIMS thesis strengthened after earnings. | — | tweet ↗ |
| 2026-08-28 | @Chill_Investing | +0.10 | Reports closing a HIMS covered call and collecting $2,822. | — | tweet ↗ |
| 2026-08-28 | @optionscjp | +0.55 | Buy these dips at the stated levels, but scale in rather than going all in. — Explicitly recommends six dip buys at specified prices while cautioning against full size. | — | tweet ↗ |
| 2026-08-28 | @TradeCycles | -0.65 | Says HIMS still looks poor and refuses to invest while its chart is bearish. | — | tweet ↗ |
| 2026-08-28 | @growthrapidly | +0.70 | Buy the listed stocks after earnings-season pullbacks. — Explicitly labels a basket of stocks as buys based on long-term fundamentals. | — | tweet ↗ |
| 2026-08-28 | @Fibonacci_TA | -0.55 | Reports HIMS breaking down below a major weekly level after previously appearing likely to hold it. | — | tweet ↗ |
| 2026-08-28 | @Investinc_Intel | +0.50 | Compares IREN's leveraged AI-infrastructure growth with HIMS's capital-efficient model. | — | tweet ↗ |
| 2026-08-28 | @Fibonacci_TA | +0.70 | Bullish weekly setup targets $39 while $30.90 holds, with $57 above a breakout. | — | tweet ↗ |
| 2026-08-28 | @BinDollarSign | -0.40 | September hike odds jumped to about 62% after Warsh's speech as yields rose. | — | tweet ↗ |
| 2026-08-28 | @PeloSwing | -0.35 | Notes an 8% decline and watches the 200DMA as potential support | — | tweet ↗ |
| 2026-08-28 | @TheLongInvest | +0.00 | Observes that HIMS had large two-way moves during the month but remains flat overall. | — | tweet ↗ |
| 2026-08-28 | @Investinc_Intel | +0.72 | Plans to load the HIMS position meaningfully if price reaches $24-$25. — Explicit forward plan to add heavily at a specified entry range. | — | tweet ↗ |
| 2026-08-28 | @ilzmcfly | -0.10 | Warns that widely shared $100 targets may not be reached, citing HIMS as a cautionary example. | — | tweet ↗ |
| 2026-08-28 | @TheRealBirnbaum | +0.80 | Interprets strong market dislike of IREN and HIMS as a contrarian bullish signal. | — | tweet ↗ |
| 2026-08-28 | @dannycheng2022 | +0.70 | Buy and size up for 2-3 days when the described volatility-hole setup appears. — Gives a forward accumulation rule based on a recurring chart pattern. | — | tweet ↗ |
| 2026-08-28 | @himshouse | -0.40 | Reports HIMS down 8% | — | tweet ↗ |
| 2026-08-28 | @alc2022 | +0.75 | Frames HIMS and DUOL as future trillion-dollar AI copilot businesses in health and education. | — | tweet ↗ |
| 2026-08-28 | @FIREDUpWealth | -0.30 | Lists six highlighted stocks down 46%-55% from their 52-week highs and asks whether readers are buying. | — | tweet ↗ |
| 2026-08-28 | @johnscharts | +0.70 | Lists large gains and losses from ideas shared during the prior 25 sessions. | — | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.